# Bipolar Disorder in Children and Adolescents

## Overview

Pediatric bipolar disorder is one of the most controversial diagnoses in child psychiatry. A dramatic increase in pediatric bipolar diagnoses occurred from the late 1990s through the 2000s, primarily in the United States, driven by a broadened conceptualization that emphasized chronic irritability rather than classic episodic mania. The introduction of Disruptive Mood Dysregulation Disorder (DMDD) in DSM-5 was a direct response to concerns about overdiagnosis. Distinguishing genuine mania from ADHD, DMDD, trauma, and normal developmental variation remains a significant clinical challenge. When accurately diagnosed, however, adolescent bipolar disorder is a serious illness requiring mood stabilizers or atypical antipsychotics.

## The Pediatric Bipolar Controversy

### The "Epidemic" (1994-2010)

Bipolar diagnoses in children increased approximately 40-fold from the mid-1990s to the mid-2000s in the United States. This surge was largely driven by influential clinicians who argued that mania in children presents as chronic, severe irritability rather than the classic episodic mood elevation seen in adults. This "broad phenotype" approach led to many chronically irritable children being diagnosed with bipolar disorder and treated with mood stabilizers and antipsychotics. The controversy was amplified by concerns about pharmaceutical industry influence and conflicts of interest.

### The Critique

International colleagues noted that the pediatric bipolar diagnosis at this scale was almost exclusively an American phenomenon. Chronic irritability lacks the episodic course, grandiosity, and decreased need for sleep that define mania. Follow-up studies demonstrated that chronically irritable children were far more likely to develop depression and anxiety in adulthood — not bipolar disorder. The broad phenotype was capturing a heterogeneous group that included ADHD, ODD, trauma responses, anxiety, and temperamental dysregulation. Many children were exposed to atypical antipsychotics with significant metabolic side effects for a diagnosis of questionable validity.

### DSM-5 Response

The DSM-5 responded to this controversy in two ways: it created DMDD as a diagnostic category for chronically irritable children, and it clarified that bipolar criteria require distinct episodes of mania or hypomania with clear changes from baseline. Mania requires elevated or expansive mood, or irritability that is episodic rather than chronic. These revisions aimed to reduce the inappropriate application of the bipolar diagnosis to children whose primary problem is chronic dysregulation.

## Clinical Presentation of Bipolar Disorder in Youth

### Adolescent Mania (Classic Presentation)

Adolescent mania more closely resembles the adult presentation. It features elevated, expansive, or irritable mood that is episodic and represents a clear change from baseline functioning. Decreased need for sleep is a key symptom — the person feels rested after only 3-4 hours of sleep, which is qualitatively different from insomnia where the person feels tired. Grandiosity manifests in age-inappropriate ways: believing they have special powers, forming unrealistic plans, defying authority with a sense of entitlement. Pressured speech, flight of ideas, and racing thoughts are present. Increased goal-directed activity or psychomotor agitation is evident. Excessive involvement in risky activities — sexual behavior, spending, reckless driving — may occur. Psychotic features are actually more common in adolescent mania than in adult mania. Duration criteria require at least 7 days for mania (or any duration if hospitalization is required) and at least 4 days for hypomania.

### Childhood Mania (When It Does Exist)

Genuine mania before puberty is rare, and very early onset (before age 10) is uncommon, requiring particularly careful assessment. When present, childhood mania tends to have a more chronic and less episodic course than adolescent-onset illness. Mixed features (simultaneous manic and depressive symptoms) are common. Psychotic features may be difficult to distinguish from imaginative play in young children. The essential requirement is demonstration of clear episodes with identifiable changes from baseline functioning.

### Bipolar Depression in Youth

Bipolar depression may be the first mood episode and is often the presenting problem. It can be indistinguishable from unipolar depression at initial presentation, making longitudinal assessment essential. Features that may suggest bipolar rather than unipolar depression include hypersomnia, psychomotor retardation, psychotic features, a strong family history of bipolar disorder, hypomania emerging with antidepressant treatment, early onset, and rapid cycling.

## Differential Diagnosis

### ADHD vs. Mania

This is the most critical differential in pediatric bipolar assessment. The two conditions share symptoms of hyperactivity, distractibility, talkativeness, and impulsivity. Key differentiators include episodicity (ADHD is chronic and pervasive while mania is episodic with identifiable onset and offset), sleep patterns (children with ADHD want to sleep but cannot settle, while manic children have genuinely decreased need for sleep and feel rested), grandiosity (children with ADHD may be overconfident but are not delusionally grandiose), mood quality (ADHD irritability is frustration-based while manic mood is elevated, euphoric, or represents a distinct change from baseline), and onset pattern (ADHD begins before age 12 with gradual recognition while manic episodes have identifiable onset points). Complicating matters further, ADHD and bipolar disorder can co-occur, with approximately 60% comorbidity in bipolar youth.

| Feature | ADHD | Mania | DMDD | Trauma/PTSD |
|---|---|---|---|---|
| Course | Chronic, pervasive | Episodic (clear onset/offset) | Chronic, non-episodic | Context-dependent; may be episodic |
| Mood Quality | Frustration-based irritability | Elevated/expansive or distinct change from baseline | Chronic irritability between outbursts | Hyperarousal, emotional numbing |
| Sleep | Wants to sleep, cannot settle | Decreased need for sleep (feels rested) | Variable | Nightmares, hypervigilance |
| Grandiosity | May be overconfident | Delusional grandiosity possible | Absent | Absent |
| Onset | Before age 12, gradual | Identifiable episode onset | Before age 10, gradual | Linked to traumatic event(s) |
| Longitudinal Outcome | Persists as ADHD | Recurrent mood episodes | Depression/anxiety in adulthood | PTSD, depression, or resolution |

### DMDD vs. Bipolar

DMDD features chronic, severe irritability with frequent outbursts but is non-episodic and lacks periods of elevated or expansive mood. Bipolar disorder features episodic mood disturbance with identifiable manic or hypomanic episodes. The two are mutually exclusive diagnoses in DSM-5. DMDD is the better fit for chronically irritable children, while bipolar disorder is reserved for episodic presentations.

### Trauma and PTSD

Trauma can produce irritability, impulsivity, sleep disturbance, emotional dysregulation, and hyperarousal that closely mimics mania. Dissociative symptoms may be mistaken for thought disorder. A thorough trauma history is essential before diagnosing bipolar disorder. Re-experiencing symptoms, avoidance, and context-dependent symptom exacerbation suggest trauma rather than bipolar disorder.

### Substance-Induced Mood Disorder

Cannabis, stimulants, hallucinogens, and alcohol can all produce manic-like symptoms. A urine drug screen should be obtained in all adolescents presenting with a first manic episode. Substance-induced mania typically resolves with sobriety.

## Pharmacotherapy

### Mood Stabilizers

#### Lithium

Lithium is FDA-approved for bipolar disorder in adolescents ages 12 and older and has the longest treatment track record. It is effective for both acute mania and maintenance treatment and has unique evidence for reducing suicidality. Dosing starts at 300 mg two to three times daily, titrating to therapeutic levels of 0.8-1.2 mEq/L for acute mania and 0.6-1.0 mEq/L for maintenance. Monitoring includes lithium levels, renal function, thyroid function, CBC, and EKG at baseline and periodically. Side effects include nausea, polyuria/polydipsia, weight gain, tremor, hypothyroidism, and acne. Lithium has a narrow therapeutic index, with toxicity risk during dehydration — hydration must be emphasized, especially for adolescent athletes. Lithium is teratogenic (Ebstein anomaly risk), making contraception counseling essential for adolescent females.

#### Valproate (Divalproex)

Valproate is used for acute mania and mixed episodes but is not recommended in females of childbearing potential due to significant teratogenicity (neural tube defects and cognitive effects in exposed offspring) and its association with polycystic ovary syndrome. Dosing starts at 250-500 mg/day, titrating to levels of 50-125 mcg/mL. Monitoring includes valproate levels, liver function tests, CBC, and ammonia if symptoms suggest hyperammonemia. Side effects include weight gain, GI symptoms, hair loss, sedation, tremor, and rare hepatotoxicity and pancreatitis.

### Atypical Antipsychotics

Several atypical antipsychotics have FDA approval for pediatric bipolar I disorder. Aripiprazole (ages 10-17) has a favorable metabolic profile. Risperidone (ages 10-17) is effective but carries weight gain and prolactin concerns. Quetiapine (ages 10-17) causes significant sedation and weight gain. Olanzapine (ages 13-17) is highly effective but has the most significant metabolic side effects. Asenapine (ages 10-17) is another approved option. All require metabolic monitoring.

### Antidepressant Use in Bipolar Youth

Antidepressants may precipitate mania or rapid cycling in bipolar patients. If an antidepressant is needed for bipolar depression, it should only be used with concurrent mood stabilizer coverage. TCAs and venlafaxine should be avoided due to higher switch risk. SSRIs may be cautiously used with mood stabilizer coverage. Lamotrigine may be preferred for bipolar depression maintenance, though it requires slow titration due to the risk of Stevens-Johnson syndrome.

<image>A diagnostic comparison table differentiating mania from ADHD, DMDD, and trauma-related dysregulation. Columns: symptom domain (mood, sleep, episodicity, grandiosity, onset, course, family history). Rows for each condition showing characteristic presentation in each domain. Use color coding to highlight key differentiating features. Include a note that ADHD and bipolar disorder can co-occur.</image>

<image>A timeline graphic showing the rise and fall of the pediatric bipolar diagnosis from 1990 to present. Show the 40-fold increase in diagnosis from mid-1990s to mid-2000s, the publication of key papers (Biederman broad phenotype, Leibenluft narrow vs. broad phenotype, Stringaris longitudinal data), the DSM-5 introduction of DMDD (2013), and the subsequent decline in pediatric bipolar diagnosis rates. Include contextual notes about the controversy at each stage.</image>

<image>A pharmacotherapy comparison chart for adolescent bipolar disorder showing lithium, valproate, and FDA-approved atypical antipsychotics (aripiprazole, risperidone, quetiapine, olanzapine, asenapine). Compare: FDA-approved age, efficacy for acute mania, efficacy for maintenance, weight gain risk, metabolic risk, key monitoring requirements, and special warnings (teratogenicity, prolactin, etc.).</image>

## Clinical Pearls

Episodicity is the key feature of bipolar disorder: symptoms must represent a distinct change from baseline rather than a chronic pattern. Chronic irritability without discrete manic episodes is not bipolar disorder — consider DMDD, ADHD, anxiety, or trauma instead. Decreased need for sleep (feeling rested after minimal sleep) is one of the most specific symptoms of mania and a powerful differentiator from ADHD. The pediatric bipolar "epidemic" was largely a US phenomenon that resulted in many children being exposed to unnecessary antipsychotic medication. When bipolar disorder is genuinely present in adolescence, it is a serious illness with high morbidity, and lithium and atypical antipsychotics are evidence-based treatments. Valproate should be avoided in adolescent females due to teratogenicity and PCOS risk. Lithium requires careful monitoring but is the only mood stabilizer with anti-suicide evidence. A urine drug screen should always be obtained in adolescents presenting with a first manic episode.

## References
- Leibenluft, E. (2011). Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. *American Journal of Psychiatry*, 168(2), 129-142.
- Moreno, C. et al. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Archives of General Psychiatry*, 64(9), 1032-1039.
- McClellan, J. et al. (2007). AACAP Practice Parameter for bipolar disorder in children and adolescents. *JAACAP*, 46(1), 107-125.
- Stringaris, A. et al. (2010). Adult outcomes of youth irritability: a 20-year prospective community-based study. *American Journal of Psychiatry*, 167(9), 1048-1054.
- Findling, R.L. et al. (2015). Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. *Pediatrics*, 136(5), 885-894.
- Kowatch, R.A. et al. (2005). Treatment guidelines for children and adolescents with bipolar disorder. *JAACAP*, 44(3), 213-235.